高龄与高危非肌层浸润性膀胱癌患者膀胱内灌注卡介苗反应降低的关联:日本泌尿肿瘤研究组JUOG-UC-1901-BCG的多机构回顾性结果
基于日本31家机构2000-2018年3283例接受膀胱内卡介苗(BCG)灌注的非肌层浸润性膀胱癌患者,将1437例高级别T1和602例Tis肿瘤患者按年龄≥75岁与<75岁分组。倾向性评分匹配前后分析显示,高级别T1肿瘤中年龄≥75岁是复发和进展的独立预后因素,匹配后870例高级别T1患者中≥75岁组BCG灌注后累积复发概率显著高于<75岁组;Tis肿瘤中未发现可预测复发和进展的变量。
要点
- 高级别T1肿瘤中,年龄≥75岁是复发和进展的独立预后因素(P=.015和P=.013)。
- 匹配后870例高级别T1患者中,≥75岁组BCG灌注后累积复发概率显著高于<75岁组(P=.008)。
- 高级别T1和Tis中,≥75岁组与<75岁组BCG灌注中断频率无显著差异(P=.564和P=.869)。
核心结论
- 高级别T1膀胱癌患者中,年龄≥75岁者膀胱内BCG灌注后累积复发概率显著高于<75岁者。
研究设计与样本
- 日本31家机构2000-2018年回顾性研究,共3283例接受膀胱内BCG灌注的非肌层浸润性膀胱癌患者。
- 1437例高级别T1和602例Tis肿瘤患者分为年龄≥75岁组与<75岁组。
- 倾向性评分匹配前采用Fine-Gray竞争风险回归多因素分析,匹配后采用累积发生率法生存分析。
主要发现
- 匹配前高级别T1肿瘤中,年龄≥75岁是复发和进展的独立预后因素(P=.015和P=.013)。
- 匹配前Tis肿瘤中未发现可预测复发和进展的变量。
- 匹配后870例高级别T1肿瘤中,≥75岁组BCG灌注后累积复发概率显著高于<75岁组(P=.008)。
- 高级别T1和Tis中,≥75岁组与<75岁组BCG灌注中断频率无显著差异(P=.564和P=.869)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the therapeutic effect of Bacille Calmette-Guérin (BCG) intravesical instillation in older and younger patients with high-risk non-muscle-invasive bladder cancer. The comparison was performed with propensity score matching (PSM) without terminating the death of the older patients using relatively large-scale retrospective data from multiple institutes in Japan. MATERIALS AND METHODS: Overall, 3283 patients diagnosed with non-muscle-invasive bladder cancer treated with intravesical BCG instillation during 2000-2018 in 31 institutes were examined; 1437 and 602 patients with high-grade T1 and Tis tumors were divided into those aged ≥75 and <75 years. Multivariate analysis using the Fine-Gray competing risks regression model before PSM and survival analysis using the cumulative incidence method after PSM were performed. RESULTS: In the pre-PSM series of high-grade T1 tumors, age ≥75 years was an independent prognostic factor for both recurrence and progression in multivariate analysis (P = .015 and P = .013). In the pre-PSM series with Tis tumor, no variables to predict recurrence and progression was found. In the post-PSM series of 870 high-grade T1 tumors, cumulative probability of recurrence after BCG intravesical instillation were significantly higher in patients aged ≥75 years than in those aged <75 years (P = .008). The frequency of discontinuation of BCG instillation in patients aged ≥75 years with high-grade T1 and Tis was not significantly different from those in patients aged <75 years (P = .564 and P = .869). CONCLUSION: The cumulative probability of recurrence after intravesical BCG instillation was significantly higher in older than in younger patients with high-grade T1 bladder cancer.
引用
- Inoue T, Miyake M, Nishimura N, et al. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG. Urology. 2022. PMID: 35700751. doi:10.1016/j.urology.2022.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。